58859-77-1

Basic information

• Product Name: 5-fluoro-1,3-dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one
• Synonyms: 5-fluoro-1,3-dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one
• CAS NO: 58859-77-1
• Molecular Weight: 235.261
• Mol File: 58859-77-1.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 5-fluoro-1,3-dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-fluoro-1,3-dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one(58859-77-1)
• EPA Substance Registry System: 5-fluoro-1,3-dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one(58859-77-1)

Safety Data

• Hazardous Substances Data: 58859-77-1(Hazardous Substances Data)

Upstream product

• 345-17-5 1-chloro-4-fluoro-2-nitrobenzene 
• 182365-86-2 tert-butyl 4-(5-fluoro-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-1-yl)piperidine-1-carboxylate 
• 1004304-10-2 tert-butyl 4-((2-amino-4-fluorophenyl)amino)piperidine-1-carboxylate 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 107618-33-7 4-(5-fluoro-2-oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylic acid ethyl ester 
• 58859-46-4 ethyl 4-aminopiperidine-1-carboxylate 
• 364-74-9 1,4-difluoro-2-nitrobenzene 
• 107618-14-4 4-(4-fluoro-2-nitro-phenylamino)-piperidine-1-carboxylic acid ethyl ester 
• 107618-21-3 4-(2-amino-4-fluoro-phenylamino)-piperidine-1-carboxylic acid ethyl ester 

Downstream Products

• 1074762-31-4 C₂₅H₃₁FN₄O 
• 1074762-34-7 C₂₅H₂₈F₄N₄O 
• 1092545-60-2 C₂₃H₂₇FN₄O₃S 
• 58859-78-2 1-{1-[4,4-bis-(4-fluoro-phenyl)-butyl]-piperidin-4-yl}-5-fluoro-1,3-dihydro-benzoimidazol-2-one 
• 521174-83-4 1-[1-(4-butyl-benzoyl)-piperidin-4-yl]-5-fluoro-1,3-dihydro-benzoimidazol-2-one 

Relevant articles and documents

Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias

While mu opioid receptor (MOR) agonists are especially effective as broad-spectrum pain relievers, it has been exceptionally difficult to achieve a clear separation of analgesia from many problematic side effects. Recently, many groups have sought MOR agonists that induce minimal βarrestin-mediated signaling because MOR agonist-treated βarrestin2 knockout mice were found to display enhanced antinociceptive effects with significantly less respiratory depression and tachyphylaxis. Substantial data now exists to support the premise that G protein signaling biased MOR agonists can be effective analgesic agents. We recently showed that, within a chemical series, the degree of bias correlates linearly with the magnitude of the respiratory safety index. Herein we describe the synthesis and optimization of piperidine benzimidazolone MOR agonists that together display a wide range of bias (G/βarr2). We identify structural features affecting potency and maximizing bias and show that many compounds have desirable properties, such as long half-lives and high brain penetration.

TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS

Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: R1 represents a group selected from H, CF3, and C1-6 alkyl (optionally substituted by C1-6 alkyloxy or triazolyl); R2/

Piperidines

Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels. More particularly, the invention provides substituted piperidines, and compositions containing these compounds. Also provided are methods using the compounds of the invention for the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrance of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a channel that includes a PN3 subunit.